pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,609 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1781Endpoints1387Fierce Biotech706BioSpace698BioPharma Dive524raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12303Rare Disease3214Immunology2862Cardiology2744Hematology2177Pulmonology2138Vaccines1794
  • Amgen Announces Retirement of Chief Technology Officer David Reese
    Amgen announced that longtime leader David Reese will retire at the end of June. Reese, 63, currently serves as the company's chief technology officer, a position he created in 2023 after many yea…
    Endpoints · 6mo agoNeutral↗ source
  • Revolution Medicines' early-stage pancreatic cancer drug shows tumor control in half of patients
    Revolution Medicines reported that its experimental therapy daraxonrasib helped control tumors in at least half of patients with early-stage pancreatic cancer, whether given alone or with chemother…
    BioPharma Dive · 6mo agoPositive readoutPositive↗ source
← prev
page 105 of 105
next →
111
globenewswire health73
fda press59
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
  • Moderna launches Phase 3 trial of mRNA bird flu vaccine after US funding cut
    Moderna has begun enrolling participants in a Phase 3 trial of its mRNA-1018 vaccine targeting H5 influenza (bird flu). The trial aims to include about 4,000 healthy adults in the United States and…
    BioPharma Dive · 6mo agoPositive↗ source
  • AbbVie allocates $1.4 billion for new 185-acre manufacturing campus in Durham, NC
    AbbVie has disclosed more details of its $100 billion pledge to the United States, setting aside $1.4 billion to build its first manufacturing campus in North Carolina. The project will cover a 18…
    Endpoints · 6mo agoDealNeutral↗ source
  • Merck commits up to $1 billion to Google Cloud partnership to accelerate AI across its operations
    Merck announced a multiyear partnership with Google Cloud, investing up to $1 billion to embed AI tools throughout its research, development, manufacturing, commercial and corporate functions. The…
    BioPharma Dive · 6mo agoDealPositive↗ source
  • Owkin launches autonomous AI scientist to accelerate drug discovery
    A new AI platform from Owkin, called K Pro, is designed to act as an autonomous "AI scientist," handling complex research questions that traditionally require teams of scientists. The system build…
    BioPharma Dive · 6mo agoPositive↗ source
  • OpenAI releases free ChatGPT for Clinicians to assist doctors, nurses and pharmacists
    OpenAI announced the launch of ChatGPT for Clinicians, a free AI‑powered tool designed for use by physicians, nurse practitioners, physician assistants and pharmacists. The service aims to help cl…
    Endpoints · 6mo agoPositive↗ source
  • BridgeBio Oncology appoints CSO Pedro Beltran as CEO, makes Neil Kumar executive chairman
    BridgeBio Oncology Therapeutics announced a leadership reshuffle aimed at strengthening its focus on KRAS-driven cancer programs. The company is replacing CEO Eli Wallace with its chief scientific…
    Endpoints · 6mo agoNeutral↗ source
  • Pharma-backed petition urges FDA to change policy on public release of drug rejection letters
    A law firm representing an unnamed pharmaceutical company has filed a petition asking the FDA to revise its new practice of publishing partially redacted drug rejection letters. The petition argue…
    Endpoints · 6mo agoRegulatoryNegative↗ source